Clinical trial
A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera
NCT07429266 is registered in ClinicalTrials.gov with Ono Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- May 25, 2026
- Completion date
- January 31, 2031
- Enrollment
- 250 (estimated)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.